CCL2 and melanoma: Though Nivolumab did not significantly alter serum cytokine profiles, in melanoma patients we observed a deviation from the physiological range for 7 out 18 cytokines tested: IL-1β, IL-6, CCL2, CXCL8, VEGF, IL-5 and IL-13 (Table 1).